Peter Kolchinsky portfolio, Q1 2025

RA Capital Management · 13F for the quarter ending Mar 31, 2025

For Q1 2025, RA Capital Management reported $6B across 85 US-listed positions, led by ASND (26.8%), PCVX (7.7%) and RYTM (5.4%). Compared with its filing for Q4 2024, Peter Kolchinsky opened 11 new positions, added to 14, reduced 4 and sold out of 15; 56 positions did not change.

The largest purchase was an addition to PCVX ($132.2M); the largest sale, the sale of the whole position in LEGN ($244.3M).

Reported value
$6B
Positions
85
In the top 10
63%
Filed
May 15
2025

Key facts

13F portfolio value
$6BQ1 2025
Positions
85
Largest holding
ASND 26.8%
New positions
11
Sold out
15
Filed
May 15, 2025

Holdings as of (Q1 2025), filed with the SEC on . Changes are measured against the filing for Dec 31, 2024. Every tracked investor's Q1 2025 13F.

Bought and sold in Q1 2025

Peter Kolchinsky: buys and sells in Q1 2025
StockMoveSharesSizeOf portfolio
Legend Biotech CorpLEGN▼ Sold out−7.51M$244.3M4.08%
Vaxcyte IncPCVX▲ Added 40%+3.5M$132.2M2.21%
SPDR Series TrustXBI▼ Sold out−1.23M$110.6M1.85%
Sionna Therapeutics IncSION▲ New+10.45M$109.3M1.82%
Axsome Therapeutics IncAXSM▼ Sold out−1M$84.6M1.41%
Verona Pharma Plcno ticker on file
▼ Sold out−1.77M$82.1M1.37%
Disc Medicine IncIRON▲ New+1.58M$78.3M1.31%
Praxis Precision MedicinesPRAX▼ Sold out−761.96K$58.6M0.98%
Recursion Pharmaceuticals IncRXRX▼ Sold out−7.73M$52.2M0.87%
Geron CorpGERN▲ Added 101%+30.37M$48.3M0.81%
89BIO Incno ticker on file
▲ Added 40%+5.71M$41.5M0.69%
Evolent Health IncEVH▼ Sold out−3.58M$40.2M0.67%
Scholar Rock Holding CorpSRRK▲ Added more than 10×+1.12M$36M0.60%
UroGen Pharma LtdURGN▲ New+3.21M$35.5M0.59%
Dyne Therapeutics IncDYN▲ Added 52%+3.33M$34.9M0.58%
Chimerix Incno ticker on file
▼ Sold out−8.8M$30.6M0.51%
Newamsterdam Pharma CompanyNAMS▲ Added 15%+1.29M$26.5M0.44%
Ascendis Pharma A/SASND▲ Added 1.7%+168.75K$26.3M0.44%
Janux Therapeutics IncJANX▲ Added 8.0%+824.04K$22.2M0.37%
Mineralys Therapeutics IncMLYS▲ Added 27%+1.3M$20.6M0.34%
Glaukos CorpGKOS▲ New+190.26K$18.7M0.31%
Metsera Incno ticker on file
▲ New+675.53K$18.4M0.31%
Dianthus Therapeutics IncDNTH▲ Added 54%+1M$18.1M0.30%
C4 Therapeutics IncCCCC▼ Sold out−4.88M$17.6M0.29%
Pliant Therapeutics IncPLRX▼ Sold out−1.28M$16.9M0.28%
Arcellx Incno ticker on file
▲ Added 8.9%+249.2K$16.3M0.27%
10X Genomics IncTXG▼ Reduced 41%−1.34M$11.7M0.19%
Third Harmonic Bio Incno ticker on file
▼ Sold out−960.62K$9.9M0.17%
Iteos Therapeutics Incno ticker on file
▲ Added 74%+1.56M$9.3M0.16%
Bright Minds Biosciences IncDRUG▼ Reduced 55%−254.4K$9.2M0.15%
Arcus Biosciences IncRCUS▲ New+1.14M$8.9M0.15%
Arvinas IncARVN▼ Sold out−421.35K$8.1M0.13%
Acadia Healthcare CompanyACHC▲ New+217K$6.6M0.11%
Beta Bionics IncBBNX▲ New+500K$6.1M0.10%
Enanta Pharmaceuticals IncENTA▼ Sold out−1.04M$6M0.10%
Humacyte IncHUMA▲ New+3.31M$5.6M0.09%
Surrozen IncSRZN▲ Added 140%+396.55K$4.6M0.08%
Kura Oncology IncKURA▼ Reduced 10%−446.43K$2.9M0.05%
Sutro BiopharmaSTRO▲ New+4.43M$2.9M0.05%
GH Research PLCGHRS▲ Added 3.9%+257.96K$2.8M0.05%
Allakos Incno ticker on file
▼ Sold out−1.13M$1.4M0.02%
Bioage Labs IncBIOA▼ Reduced 20%−258.1K$970.4K0.02%
CytomX Therapeutics IncCTMX▲ New+1M$635.8K0.01%
Regulus Therapeutics Incno ticker on file
▼ Sold out−336.84K$532.2K0.01%

Holdings at the quarter's end

Peter Kolchinsky holdings, Q1 2025
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q4 2024
1Ascendis Pharma A/SASND · SPONSORED ADRHealth Care26.8%$1.6B10.28M$155.864+ qtrs▲ Added 1.7%
2Vaxcyte IncPCVXHealth Care7.69%$460.3M12.19M$37.764+ qtrs▲ Added 40%
3Rhythm Pharmaceuticals IncRYTMHealth Care5.38%$322.3M6.08M$52.974+ qtrsNo change
4Janux Therapeutics IncJANX—5.05%$302.1M11.19M$27.004+ qtrs▲ Added 8.0%
5Newamsterdam Pharma CompanyNAMS—3.47%$207.5M10.14M$20.474+ qtrs▲ Added 15%
6
Arcellx Incno ticker on file · SH
—3.33%$199.2M3.04M$65.604+ qtrs▲ Added 8.9%
7Edgewise Therapeutics IncEWTXHealth Care3.27%$196M8.91M$22.004+ qtrsNo change
8
Avidity Biosciences Incno ticker on file · SH
—3.11%$186M6.3M$29.524+ qtrsNo change
9Wave Life Sciences LtdWVE—2.46%$147.1M18.2M$8.084+ qtrsNo change
10
89BIO Incno ticker on file · SH
—2.42%$144.6M19.89M$7.274+ qtrs▲ Added 40%
11Ars Pharmaceuticals IncSPRY—2.28%$136.6M10.86M$12.584+ qtrsNo change
12Sionna Therapeutics IncSION—1.83%$109.3M10.45M$10.461 qtrNew
13Lenz Therapeutics IncLENZ—1.79%$107.4M4.18M$25.714+ qtrsNo change
14Dyne Therapeutics IncDYN · SH—1.70%$101.6M9.71M$10.464+ qtrs▲ Added 52%
15Tyra Biosciences IncTYRA—1.65%$98.9M10.64M$9.304+ qtrsNo change
16Mineralys Therapeutics IncMLYS—1.63%$97.6M6.15M$15.884+ qtrs▲ Added 27%
17Geron CorpGERN—1.60%$96M60.38M$1.594+ qtrs▲ Added 101%
18RxSight IncRXST · SH—1.58%$94.5M3.74M$25.254+ qtrsNo change
19Bicara Therapeutics IncBCAX—1.51%$90.6M6.96M$13.033 qtrsNo change
20Disc Medicine IncIRON—1.31%$78.3M1.58M$49.641 qtrNew
21GH Research PLCGHRS—1.28%$76.6M6.94M$11.034+ qtrs▲ Added 3.9%
22
Apogee Therapeutics Incno ticker on file · SH
—0.98%$58.6M1.57M$37.364+ qtrsNo change
23Dianthus Therapeutics IncDNTHHealth Care0.87%$52M2.87M$18.144+ qtrs▲ Added 54%
24Zai Lab LtdZLAB · ADR—0.78%$46.8M1.3M$36.142 qtrsNo change
25
Day One Biopharmaceuticalsno ticker on file · SH
—0.76%$45.6M5.76M$7.934+ qtrsNo change
26Septerna IncSEPN—0.68%$40.5M7M$5.792 qtrsNo change
27
Tourmaline Bio Incno ticker on file · SH
—0.65%$38.6M2.54M$15.214+ qtrsNo change
28Climb Bio IncCLYM—0.64%$38.3M31.42M$1.224+ qtrsNo change
29Scholar Rock Holding CorpSRRK · SHHealth Care0.61%$36.5M1.14M$32.152 qtrs▲ Added more than 10×
30UroGen Pharma LtdURGN · SH—0.59%$35.5M3.21M$11.061 qtrNew
31Artiva Biotherapeutics IncARTV—0.49%$29.6M9.85M$3.003 qtrsNo change
32Fulcrum Therapeutics IncFULC—0.49%$29.5M10.23M$2.884+ qtrsNo change
33Vor Biopharma IncVOR · SH—0.48%$28.4M39.65M$0.71754+ qtrsNo change
34
Astria Therapeutics Incno ticker on file · SH
—0.46%$27.3M5.11M$5.344+ qtrsNo change
35Kura Oncology IncKURA · SH—0.44%$26.4M4M$6.602 qtrs▼ Reduced 10%
36Structure Therapeutics IncGPCR · SH—0.44%$26.3M1.52M$17.314+ qtrsNo change
37
Cidara Therapeutics Incno ticker on file · SH
—0.39%$23.5M1.09M$21.543 qtrsNo change
38
Aerovate Therapeutics Incno ticker on file · SH
—0.39%$23.1M9.19M$2.514+ qtrsNo change
39IDEAYA Biosciences IncIDYA · SH—0.37%$22.1M1.35M$16.383 qtrsNo change
40
Iteos Therapeutics Incno ticker on file · SH
—0.36%$21.8M3.65M$5.974+ qtrs▲ Added 74%
41Travere Therapeutics IncTVTXHealth Care0.34%$20.6M1.15M$17.922 qtrsNo change
42Nkarta IncNKTX—0.33%$19.9M10.81M$1.844+ qtrsNo change
43Glaukos CorpGKOS · SHHealth Care0.31%$18.7M190.26K$98.421 qtrNew
44Monopar Therapeutics IncMNPR—0.31%$18.6M511.21K$36.412 qtrsNo change
45
Metsera Incno ticker on file · SH
—0.31%$18.4M675.53K$27.221 qtrNew
46Eyepoint Pharmaceuticals IncEYPT · SH—0.29%$17.2M3.18M$5.422 qtrsNo change
4710X Genomics IncTXG · SHHealth Care0.28%$17M1.94M$8.732 qtrs▼ Reduced 41%
48Acrivon Therapeutics IncACRV—0.28%$16.9M8.34M$2.034+ qtrsNo change
49Enliven Therapeutics IncELVN · SH—0.28%$16.7M848.99K$19.684+ qtrsNo change
50Acumen Pharmaceuticals IncABOS—0.27%$16.4M14.93M$1.104+ qtrsNo change
51Solid Biosciences IncSLDB—0.27%$16M4.33M$3.704+ qtrsNo change
52Ceribell IncCBLL · SH—0.27%$15.8M824.58K$19.212 qtrsNo change
53Nurix Therapeutics IncNRIX · SH—0.27%$15.8M1.33M$11.882 qtrsNo change
54Insmed IncINSM · SHHealth Care0.26%$15.3M200K$76.294+ qtrsNo change
55Taysha Gene Therapies IncTSHA—0.25%$15.1M10.87M$1.394+ qtrsNo change
56Pepgen IncPEPG—0.25%$15M10.69M$1.414+ qtrsNo change
574D Molecular TherapeuticsFDMT—0.25%$14.7M4.56M$3.234+ qtrsNo change
58Protara Therapeutics IncTARA · SH—0.24%$14.5M3.4M$4.264+ qtrsNo change
59Larimar Therapeutics IncLRMR · SH—0.22%$13M6.05M$2.154+ qtrsNo change
60Eledon Pharmaceuticals IncELDN · SH—0.20%$12.1M3.57M$3.392 qtrsNo change
61Alector IncALEC · SH—0.20%$11.9M9.7M$1.232 qtrsNo change
62Sera Prognostics IncSERA · SH—0.19%$11.2M3.03M$3.684+ qtrsNo change
63MBX Biosciences IncMBX · SH—0.19%$11.2M1.51M$7.383 qtrsNo change
64Bicycle Therapeutics PlcBCYC · SH—0.16%$9.3M1.09M$8.494+ qtrsNo change
65Arcus Biosciences IncRCUS · SH—0.15%$8.9M1.14M$7.851 qtrNew
66Surrozen IncSRZN · SH—0.13%$7.9M679.13K$11.664+ qtrs▲ Added 140%
67Immatics N.V.IMTX · SH—0.13%$7.9M1.75M$4.514+ qtrsNo change
68Avalo Therapeutics IncAVTX—0.13%$7.7M967K$8.013 qtrsNo change
69
Perceptive Cap Solutionsno ticker on file
—0.13%$7.7M750K$10.304+ qtrsNo change
70Bright Minds Biosciences IncDRUG—0.12%$7.4M206.43K$36.072 qtrs▼ Reduced 55%
71Aclaris Therapeutics IncACRS—0.12%$7.1M4.67M$1.532 qtrsNo change
72Acadia Healthcare CompanyACHC · SH—0.11%$6.6M217K$30.321 qtrNew
73Beta Bionics IncBBNX · SH—0.10%$6.1M500K$12.241 qtrNew
74Xencor IncXNCR—0.10%$6.1M575K$10.643 qtrsNo change
75Werewolf Therapeutics IncHOWL—0.10%$6M6.14M$0.97224+ qtrsNo change
76Adicet Bio IncACET · SH—0.10%$5.7M7.54M$0.75504+ qtrsNo change
77Humacyte IncHUMA · SH—0.09%$5.6M3.31M$1.711 qtrNew
78Zura Bio LtdZURA · SH—0.07%$4.2M3.22M$1.294+ qtrsNo change
79Bioage Labs IncBIOA—0.07%$4M1.05M$3.763 qtrs▼ Reduced 20%
80Boundless Bio IncBOLD · SH—0.06%$3.3M2.18M$1.514+ qtrsNo change
81
Newamsterdam Pharma Co NV-27no ticker on file · WTS
—0.05%$3M333.33K$8.994+ qtrsNo change
82Sutro BiopharmaSTRO · SH—0.05%$2.9M4.43M$0.65061 qtrNew
83Lexeo Therapeutics IncLXEO—0.03%$1.9M546.55K$3.474+ qtrsNo change
84CytomX Therapeutics IncCTMX · SH—0.01%$635.8K1M$0.63581 qtrNew
85
Scilex Holding Cono ticker on file · SH
—0.00%$257.5K1.04M$0.24854+ qtrsNo change

By sector

Peter Kolchinsky portfolio by sector, Q1 2025
SectorShare of portfolioValuePositions
Health Care45.8%$2.7B10
No sector on file54.2%$3.2B75

Questions and answers

What did Peter Kolchinsky own in Q1 2025?

RA Capital Management's 13F for Q1 2025 lists 85 positions worth $6B. The largest: ASND (26.8%), PCVX (7.7%), RYTM (5.4%), JANX (5.0%), NAMS (3.5%).

What did Peter Kolchinsky buy in Q1 2025?

The largest purchases, by the shares bought at the quarter-end price the filing implies: PCVX (added, $132.2M), SION (new, $109.3M), IRON (new, $78.3M), GERN (added, $48.3M), 89BIO Inc (added, $41.5M), SRRK (added, $36M).

What did Peter Kolchinsky sell in Q1 2025?

The largest sales: LEGN (sold out, $244.3M), XBI (sold out, $110.6M), AXSM (sold out, $84.6M), Verona Pharma Plc (sold out, $82.1M), PRAX (sold out, $58.6M), RXRX (sold out, $52.2M).

When was this filing made?

RA Capital Management filed its 13F for the quarter ending Mar 31, 2025 on May 15, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Peter Kolchinsky portfolio, Q1 2025: RA Capital Management 13F holdings”, data as of 15 May 2025. https://funkfolio.com/gurus/peter-kolchinsky/2025-q1

Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Mar 31, 2025.

Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Mar 31, 2025, filed May 15, 2025. Changes compare share counts with the filing for Dec 31, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $6B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 4 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.